Endothelial nitric oxide synthase produces nitric oxide which is involved in many physiologic regulatory functions. Variable number of tandem repeats in intron 4 of endothelial nitric oxide synthase gene are reported to be associated with blood pressure regulation. Nitric oxide is involved in regulation of cardiomyocyte genes but it is not known If endothelial nitric oxide synthase 4 gene polymorphisms are related with left ventricular hypertrophy. We studied endothelial nitric oxide synthase 4a/b allele status in hypertensive and normotensive patients and echocardiographic parameters in a subgroup of hypertensive group. We performed a case-control study involving 110 Turkish hypertensive patients and 87 controls. All subjects were genotyped for endothelial nitric oxide synthase 4a/b polymorphism. Echocardiographic measurements were obtained in 94 of the hypertensive patients. Endothelial nitric oxide synthase 4a/b genotype frequencies were 6.4%, 23.6%, 70% in hypertensives and 1.1%, 18.4%, 80.5% in controls for a/a, a/b, b/b, respectively. Left ventricular dimensions, mass and diastolic indices were not different across endothelial nitric oxide synthase 4 genotypes. Patients with 4a/a genotype had higher interventricular septal thickness than the other group; 14.83(1.6), 11.91(1.51), 12.21(1.56) for a/a, a/b, b/b, respectively and p = 0.0001. Endothelial nitric oxide synthase 4a/b gene polymorphism is not associated with hypertension in Turkish patients. 4a/a genotype was associated with higher interventricular septal thickness in hypertensive patients.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease resulting from the accumulation of genetic changes that affect the development of T-cells. The precise role of lymphoid enhancer-binding factor 1 (LEF1) in T-ALL has been controversial since both overexpression and inactivating LEF1 mutations have been reported to date. Here, we investigate the potential gene targets of LEF1 in the Jurkat human T-cell leukemia cell line. We used small interfering RNA (siRNA) technology to knock down LEF1 in Jurkat cells and then compared the gene expression levels in the LEF1 knockdown cells with nontargeting siRNA-transfected and non-transfected cells by employing microarray analysis. We identified DHRS2, a tumor suppressor gene, as the most significantly downregulated gene in LEF1 knockdown cells, and we further confirmed its downregulation by real-time quantitative polymerase chain reaction (qRT-PCR) in mRNA and at protein level by western blotting. Our results revealed that DHRS2 is positively regulated by LEF1 in Jurkat cells, which indicates the capability of LEF1 as a tumor suppressor and, together with previous reports, suggests that LEF1 exhibits a regulatory role in T-ALL via not only its oncogenic targets but also tumor suppressor genes.
29 January 2020 in JCR: Journal of Clinical Rheumatology
Background Behçet disease (BD) belongs to a disease family that has a transparent borderline between autoinflammatory and autoimmune disorders. Fas and some miRNAs have revealed to display remarkable roles in both autoimmune and autoinflammatory processes, and they can play important roles in defective apoptosis in BD. We investigated the association of the susceptibility of BD with Fas, miRNA variations, and their both single and combined presence in a Turkish population as a case-control study. Methods The distributions of FAS-670 A>G rs1800682, mir146a rs2910164, and mir196a rs11614913 polymorphisms are analyzed with the polymerase chain reaction–restriction fragment length polymorphism method in 115 BD patients and 220 controls in 6-month period. Results Statistical analysis indicates that in the case of Fas-670 A/G rs1800682, AA genotype and A allele have a protective role in BD (p = 0.0004 and p = 0.0009, respectively). The dominant model (AA + AG/GG) also displays a protective effect on BD unlike the recessive model (p = 0.03). In addition, both homozygous genotype (CC) of rs2910164 of mir-146a (p = 0.04) and the dominant model (CC + CG vs. GG) have protective effects on BD unlike the recessive model (p < 0.0001). Both mir-196a2 rs1800682 polymorphism and combined genotype analysis of rs1800682-rs2910164 and rs1800682-rs11614913 gave no statistically significant differences within the groups for genotypes and either of the alleles (p > 0.05). Conclusions These findings indicate that both Fas rs1800682 and mir-146a rs2910164 variants might be important factors participating in the protection against BD in the Turkish population.
Background. Ferroptosis resistance in KRAS-mutant colorectal cancer (CRC) runs through at least two independent axes — the GPX4–glutathione pathway and the FSP1–CoQ10–NAD(P)H pathway — and KRAS-mutant cells specifically upregulate FSP1 via MAPK and NRF2. Selective inhibition of GPX4 or SLC7A11 alone leaves FSP1 resistance intact, and no single compound with dual GPX4 and FSP1 activity has been reported. Methods. We ran cross-target docking of eleven compounds against the crystal structure of human FSP1 (PDB 8WIK, 2.00 Å, with 6-OH-FAD and NAD) using AutoDock Vina 1.2.7 [8], targeting the CoQ10/catalytic pocket and the NAD-binding allosteric cavity. The set comprised two GPX4 candidates (JKE-1674, ClAcNH_001) from prior docking against PDB 7KTC, one SLC7A11 candidate (PipAryl_005) from PDB 7P9U, two reference FSP1 inhibitors (iFSP1, FSEN1), and six de novo CoQ10-pharmacophore scaffolds. All compounds were profiled for Lipinski compliance, PAINS status, and ADMET in RDKit. Vertical electron affinities were computed at r2SCAN-3c/CPCM(water) in ORCA 5.0 [26] to assess the redox liability of quinone scaffolds. Results. JKE-1674 (GPX4 − 8.83 kcal/mol) scored − 9.90 at the FSP1 CoQ pocket, approaching the iFSP1 reference (− 10.10). PipAryl_005 (SLC7A11 − 8.47 kcal/mol) scored − 10.60, exceeding iFSP1 at both FSP1 sites. Among the de novo scaffolds, Quinone_002 (QED 0.916, − 9.80) and CoQ_Mimic_002 (QED 0.899, − 9.20) ranked highest. Quantum-chemical calculations confirmed that naphthoquinone scaffolds have electron affinities within the CoQ0 substrate range, validating their quinone_A PAINS flags; the dimethoxybenzene CoQ_Mimic_001 (EA 1.26 eV) is redox-inert. Four PAINS-clean, Lipinski-compliant compounds were advanced as priority candidates. Conclusions. JKE-1674 and PipAryl_005 carry in silico dual GPX4–FSP1 and triple SLC7A11–FSP1 profiles against the experimental 8WIK receptor, both with better drug-likeness than iFSP1. FSP1 enzymatic assays (DCPIP) and SPR are the required next steps before either compound is described as a confirmed multi-pathway inhibitor.